{"organizations": [], "uuid": "c07b3d872ec0165609f509af48da22b0c479e0d2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180219.html", "section_title": "Archive News &amp; Video for Monday, 19 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-oasmia-pharma-says-all-patients-ha/brief-oasmia-pharma-says-all-patients-have-been-treated-in-two-ongoing-studies-with-docecal-idUSFWN1Q901N", "country": "US", "domain_rank": 408, "title": "BRIEF-Oasmia Pharma says all patients have been treated in two ongoing studies with Docecal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.974, "site_type": "news", "published": "2018-02-19T15:36:00.000+02:00", "replies_count": 0, "uuid": "c07b3d872ec0165609f509af48da22b0c479e0d2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-oasmia-pharma-says-all-patients-ha/brief-oasmia-pharma-says-all-patients-have-been-treated-in-two-ongoing-studies-with-docecal-idUSFWN1Q901N", "ord_in_thread": 0, "title": "BRIEF-Oasmia Pharma says all patients have been treated in two ongoing studies with Docecal", "locations": [], "entities": {"persons": [], "locations": [{"name": "usa", "sentiment": "none"}, {"name": "russia", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-oasmia pharma", "sentiment": "negative"}, {"name": "oasmia pharmaceutical ab", "sentiment": "negative"}, {"name": "eu", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "stockholm newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 19 (Reuters) - Oasmia Pharmaceutical AB:\n* REG-OASMIA PHARMACEUTICAL’S DOCECAL PROGRAM ACHIEVES SIGNIFICANT DEVELOPMENT MILESTONE\n* SAYS ‍ANNOUNCES THAT ALL PATIENTS HAVE BEEN TREATED IN TWO ONGOING STUDIES WITH DOCECAL IN METASTATIC BREAST CANCER\n* SAYS THE WORK TO COMPILE THE RESULTS IS ONGOING * SAYS POSITIVE RESULTS FROM THE STUDY PROGRAM WILL BE SUFFICIENT TO APPLY FOR SALES- AND MARKETING APPROVAL IN RUSSIA, WHICH IS ONE OF THE WORLD’S FASTEST GROWING ONCOLOGY MARKETS\n* OASMIA PLANS TO SUBMIT FOR APPROVAL DURING THE SECOND HALF OF 2018\n* INTENDS TO INITIATE DISCUSSIONS REGARDING POSSIBLE REGISTRATION OF DOCECAL BASED ON THE CURRENT PROGRAM WITH EMA FOR THE EU AND WITH THE FDA FOR THE USA​ Source text for Eikon: Further company coverage: (Stockholm Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-19T15:36:00.000+02:00", "crawled": "2018-02-20T14:28:58.000+02:00", "highlightTitle": ""}